Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

What were the most important lessons in Life Sciences in 2019?

Posted on December 20th, 2019 by in Pharma R&D

As 2019 comes to a close, we asked members of Elsevier’s Life Sciences team:

What were the biggest lessons or most noteworthy developments in the Life Sciences industry this year?

(more…)

Elsevier uses machine learning to benefit pharmacovigilance

Posted on November 7th, 2019 by in Pharmacovigilance

Monitoring the scientific literature for adverse drug reactions (ADRs) is critical to maintaining drug safety, and there is no room for error. As regulations tighten, pharmacovigilance teams are seeking better strategies and methods for ensuring that all ADRs are identified in the most effective and efficient way possible.

(more…)

Global Dominance in AI? China’s Got a Plan For That

Posted on July 9th, 2019 by in Pharma R&D

Artificial intelligence is more than just a ‘hot topic’ in the pharmaceutical industry—it is actually influencing the way that major industry players and even entire nations are thinking about the future. As more AI-focused companies are launching, and as investment in AI technology is increasing in the US and EU, China is speeding up its efforts to ensure that it can be competitive in this burgeoning area.

(more…)

Healthcare Organizations, Including Major Pharmas, Band Together to Form AI-focused Group

Posted on June 26th, 2019 by in Pharma R&D

Artificial intelligence continues to gain momentum across industries as people start to better realize its potential benefits. Healthcare is no exception, as industry players understand that AI and machine learning can do much to improve patient treatment and care. Now, some in this sector want to do more to address the burgeoning challenges of AI head-on.

(more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 9